pyrroles has been researched along with Lymphopenia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL | 1 |
| Aieta, M; Amadori, D; Baldazzi, V; Basso, U; Burattini, L; Camerini, A; Chiuri, VE; De Giorgi, U; De Vincenzo, F; Ferrari, V; Fornarini, G; Lo Re, G; Luzi Fedeli, S; Masini, C; Moscetti, L; Rihawi, K; Rosti, G; Sava, T; Scarpi, E | 1 |
| Chen, S; Ford, DM; Moberly, JB; Mochizuki, T; Truitt, KE; Vollmer, TL; Zahir, H | 1 |
1 trial(s) available for pyrroles and Lymphopenia
| Article | Year |
|---|---|
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome | 2014 |
2 other study(ies) available for pyrroles and Lymphopenia
| Article | Year |
|---|---|
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphopenia; Male; Neoplasm Staging; Neutropenia; Prognosis; Pyrroles; Risk Factors; Sunitinib; Treatment Outcome | 2014 |
Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients.
Topics: Administration, Oral; Amino Alcohols; CD4-Positive T-Lymphocytes; Dose-Response Relationship, Immunologic; Down-Regulation; Humans; Lymphocyte Subsets; Lymphopenia; Lysophospholipids; Multiple Sclerosis; Pilot Projects; Pyrroles; Receptors, Lysosphingolipid; Sphingosine | 2012 |